











doi:10.101Melphalan 180 mg/m2 Can Be Safely Administered As
Conditioning Regimen before an Autologous Stem Cell
Transplantation (ASCT) in Multiple Myeloma Patients
with Creatinine Clearance 60 mL/min/1.73 m2 or Lower
with Use of Palifermin for Cytoprotection: Results of
a Phase I Trial
Muneer H. Abidi,1,3 Rishi Agarwal,2 Lois Ayash,1,3 Abhinav Deol,1,3 Zaid Al-Kadhimi,1,3
Judith Abrams,1,3 Simon Cronin,1 Marie Ventimiglia,1 Lawrence Lum,1,3 Jeffrey Zonder,1,3
Voravit Ratanatharathorn,1,3 Joseph Uberti1,32High-dose melphalan 140 mg/m is the standard of care for patients with multiple myeloma (MM) with renal
insufficiency (RI). Palifermin as a cytoprotective agent has demonstrated efficacy in reducing the intensity and
duration of oral mucositis (OM) in patients who receive intensive chemotherapy/radiotherapy. There is no
prospective data on the use of palifermin in patients with MM with RI. Eligibility criteria: creatinine clearance
#60 mL/minute/1.73 m2, age .18 years, no dialysis, no active OM, and a suitable candidate for autologous
stem cell transplant (ASCT). Melphalan dose ranged from 140 to 200 mg/m2 and escalated at the increment
of 20 mg/m2. Six dosages of palifermin 60 mcg/kg/day were given intravenously between day –5 to day 13.
Dose escalations were to stop if dose-limiting toxicities (DLTs) occurred at melphalan dose in $2 of 3
patients, with that dose declared as the maximal administered dose and the level below where #1 of 6
patients had DLTs was considered the maximally tolerated dose (MTD). Nineteen patients were enrolled
from June 2007 to June 2011. Data on 15 evaluable patients is reported as 4 patients were removed. Median
age was 59 years (range, 36-67 years). The overall incidence of OM$ grade 3 was 53% (8 of 15) and a median
duration of $grade 3 OM was 6.5 days (range, 3-42 days). One patient in L2 (melphalan 160 mg/m2) devel-
oped atrial fibrillation on day 19. Two patients in L4 (melphalan 200 mg/m2) developed grade 4 OM, hence
reaching DLT. No DLT was observed in 6 patients enrolled in L3 (melphalan 180 mg/m2). Palifermin has
permitted safe dose escalation of melphalan up to 180 mg/m2 in patients with RI.
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Renal failure is present in 20% to 50% patients
with multiple myeloma (MM) and plays a significant
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6/j.bbmt.2012.03.010Although autologous stem cell transplant (ASCT)
with high-dose melphalan conditioning is considered
the standard of care for myeloma [6-11], patients
with renal insufficiency (RI) are often excluded from
studies involving ASCT due to increased treatment-
related morbidity and mortality. However, multiple
studies have shown that RI should not be an exclusion
criterion and early ASCT could be helpful in treating
patients with MM with RI [2-5]. Melphalan 200
mg/m2 is the recommended dose of conditioning
regimen for patients with normal renal function
[11,12]. Due to increased morbidity and mortality
observed with melphalan 200 mg/m2 in patients with
RI, it is recommended that the dose of melphalan
should be reduced to 140 mg/m2 [5,13]. It is evident
that renal failure is associated with increased toxicity
of melphalan [2,3,5,13]. Badros et al. [13] showed1455
1456 Biol Blood Marrow Transplant 18:1455-1461, 2012M. H. Abidi et al.that melphalan 200 mg/m2 without a cytoprotective
agent is associated with a higher incidence of oral mu-
cositis (OM; 93%) along with other drug-related toxic-
ities. This led them to decrease the melphalan dose to
140 mg/m2 in patients with serum creatinine .2 mg/
dL. Despite reduced melphalan dose and patients re-
ceiving standard supportive care only, the incidence
of OM was 67%. Therefore, OM prevention is a pre-
requisite for dose intensification of melphalan in pa-
tients with RI.
Unfortunately, there is a considerable dearth of lit-
erature prospectively addressing this issue due to lack
of suitable supportive care options. Currently, pallia-
tion and treatment of OM is achieved through topical
and systemic analgesia [14]. Novel agents such as vela-
fermin (no longer available) and amifostine have been
evaluated with mixed results [15-17]. They have not
been shown to improve outcomes, and thus there are
no consensus recommendations for their use.
Palifermin (Kepivance) is a recombinant human
keratinocyte growth factor, which is approved for de-
creasing the incidence and duration of severe OM in
patients with hematological malignancies undergoing
chemo/radiotherapy followed by stem cell rescue
[18-23]. Spielberger et al. [21] reported that severe
OMwas reduced to 63% in the palifermin group com-
pared with 98% in the placebo group. These measures
can add considerable expense to the cost of ASCT.
However, this disbursement can be justified if these cy-
toprotective agents prevent melphalan dose reduction
in patients with myeloma with RI and result in im-
provement of response, OM, toxicity profile, and qual-
ity of life.
This phase I dose escalation trial was designed to
find the maximal tolerated dose (MTD) of melphalan
combined with palifermin in patients with RI who
were undergoing ASCT for MM. To the best of our
knowledge, there are no studies that have specifically
addressed the role of any cytoprotective agent in pa-
tients with MM with RI undergoing ASCT.MATERIALS AND METHODS
This phase I trial was registered in the clinical-
trials.gov database (NCT00482846). The study was
conducted at Karmanos Cancer Institute, Detroit,
Michigan, and was approved by the Wayne State Uni-
versity Institutional Review Board. It was conducted in
accordance with the Declaration of Helsinki.
Eligibility
Patients were eligible for the study if they qualified
for ASCT per institutional criteria and had at least
2.0  106 CD341 cells/kg cryopreserved for ASCT.
They also had to have an Eastern Cooperative
Oncology Group performance status of #2, stage 2to 3 MM, age $18 years, creatinine clearance #60
mL/minute/1.73 m2, total bilirubin \1.5  institu-
tional upper limit of normal, and an aspartate
aminotransferase/alanine aminotransferase \3  in-
stitutional upper limit of normal. Patients with base-
line oral lesions, a history of allergic reactions to
melphalan, dependence on dialysis, and prior exposure
to palifermin were deemed ineligible.
Dose Calculations
The melphalan dose was calculated using
actual body weight (ABW) except when the ABW
was .40% above the ideal body weight (IBW), and
then adjusted body weight (AdBW) was used. Men:
IBW (kg) 5 50 1 0.91  (height in cm 152); women:
IBW (kg) 5 45 1 0.91  (height in cm 152) and
AdBW (kg) 5 IBW 1 0.25  (actual weight 2 IBW).
Palifermin was administered on days 25,24, and
23 and then repeated on day11,12, and13 (periph-
eral blood stem cells infused on day 0). Palifermin dose
was 60 mcg/kg/day of ABW unless ABW was .40%
above the IBW, and then AdBW was used for dose.
There was a 24-hour interval between palifermin and
melphalan administration. Participants received pali-
fermin as once daily intravenous bolus. No study
drug dose adjustments were allowed. Filgrastim 5
mcg/kg/day was administered subcutaneously, starting
on day16, and continued until the absolute neutrophil
count was .1500/mm3 for 3 consecutive days.
In order tominimize the effect of confounding vari-
ables, use of agents such as amifostine, oral cryotherapy
during chemotherapy administration, ‘‘magic mouth-
wash’’ or ‘‘miracle mouthwash’’ solutions containing
chlorhexidine or hydrogen-peroxide or benadryl,
IL-11(Neumega), granulocyte macrophage-colony
stimulating factor, sucralfate in suspension form,
povidone-iodine rinses, glutamine as a prophylactic
agent for OM, and other investigational agents, were
not allowed during the study. Use of sucralfate tablets
was not prescribed.
Study Design
Dose level 1 began with melphalan at 140 mg/m2
with palifermin. If there no grade 3 dose-limiting tox-
icity (DLT) events were noted by day 30 after ASCT,
an additional cohort of 3 patients was entered at the
next dose level. Subsequent dose escalations were
planned at 20 mg/m2 increments in cohorts of 3 pa-
tients. Dose escalations were to stop if 2 or more
DLT events occurred at melphalan dose, with that
dose declared as the maximal administered dose. If
a single DLT was noted in a cohort of 3 patients, 3 ad-
ditional patients were entered at that dose, and dose es-
calation proceeded only if no additional DLTs (ie, 1 of
6) were noted. If 1 or more of these 3 additional pa-
tients suffered DLTs, then dose escalations were to
Table 1. Who Oral Mucositis Assessments Scale










The following was used as guidance in the oral mucositis assessments:
Grade 1 may include buccal mucosal scalloping with or without
erythema. No ulcers. Patient can swallow solid diet.
Grade 2 may include ulcers with or without erythema. Patient can
swallow solid diet.
Grade 3 may include ulcers with or without (extensive) erythema.
Patient is able to swallow liquid, but not solid diet.
Grade 4mean mucositis to the extent that alimentation is not possible.
If total parenteral nutrition was started for reasons other than mucosi-
tis, a determination of the subject’s ability to swallow must be made
using the above criteria.
Table 2. Patient Characteristics
No. of Patients (%)
Male gender 8 (53)
Median age (range) 59 (36-67)
White race 12 (80)
Median creatinine clearance, mL/minute (range) 42.8 (29-60)
CKD staging
Stage 2 1 (7)
Stage 3 13 (87)
Stage 4 1 (7)
Stage 5 0
Durie-Salmon staging
Stage III B 8 (53)
Stage III A 0
Stage III, creatinine at the time of diagnosis
not available
4 (27)
Stage II B 3 (20)
Isotypes
IgG kappa 5 (33)
IgG lambda 3 (20)
IgA kappa 2 (13)
IgD lambda 1 (7)
Kappa light chain 3 (20)
Lambda light chain 1 (7)
Previous treatment regimen
One regimen 5 (33)
Two regimen 10 (67)











Days in the hospital (range) 16 (12-74)
Median follow-up in months for those who were
alive at day 100 (range)
16.5 (3-44)
CKD indicates chronic kidney disease; BMT, bone marrow transplant;
VGPR, very good partial response; PD, progressive disease; CR,
complete response; PR, partial response; SD, stable disease.
A <50 % reduction in serum M-protein, or if the patient has light chain
disease only, a <50% reduction in the urine M-protein (Bence Jones
Protein).
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istered dose. MTD was the highest dose level below
the maximally administered dose in which #1 DLTs
were observed in 6 patients at that level. If a full cohort
of 3 patients were entered at a given level without the
observation of grade $3 palifermin-related toxicity,
but follow-up of day130 was not achieved in all 3 pa-
tients, dose escalation was still permitted to the next
level. A patient not receiving all 6 doses of palifermin
was replaced in the same dose level. Swedish Orphan
Biovitrum pharmaceuticals provided palifermin as an
investigational agent for this clinical trial. Palifermin
is commercially available, and the approximate cost
of a 5-mg vial is US $4700.
Dose-Limiting Toxicities
Grade $3 hematological toxicity was considered
acceptable for this study. Grade 4 oral mucositis, grade
4 diarrhea, $grade 3 skin rash, grade 4 elevations of
amylase and lipase (symptomatic), and $grade 3 car-
diac toxicity were considered as DLTs. Any other
grade 3 toxicity that is determined by the principal in-
vestigator to be probably or definitely related to study
drugs will be considered as a DLT.
Patient Monitoring and Follow-Up
Patients who received all 6 doses of palifermin
were followed until day 1100 as part of the protocol
and underwent workup to determine the response to
treatment on day128 and day 100 (1/2 7 days). Start-
ing on day –2, or with the administration of high-dose
melphalan, oral cavity assessments were performed
daily using the World Health Organization (WHO)
oral toxicity scale and continued until OM resolved
completely (WHO 5 0) or until day 128 (Table 1).
The bone marrow transplant attending physician
scheduled for inpatient rounding performed daily
OM assessments during the inpatient stay. If the pa-
tient was discharged from the hospital without com-
plete resolution of OM, they were followed twice
weekly in the outpatient clinic until complete resolu-tion. The bone marrow transplant attending physician
in the outpatient clinic performed this assessment. Our
primary objective was to determine the MTD of mel-
phalan in patients with RI who underwent ASCT for
myeloma when treated with palifermin to prevent
OM. The evaluation of the efficacy of this regimen,
regimen-related toxicities, and the overall response
to therapy at day 1100 constituted the secondary ob-
jectives.RESULTS
Between June 2007 and June 2011, 19 patients were
enrolled in the trial. Four patients did not receive full
doses of palifermin and were rendered nonevaluable.
The median age was 59 years (range, 36-67 years).
Eight patients were men. The median creatinine clear-
ance was 42.8 mL/minute (range, 29-60 minute).








Level 1 – M 140
1 2-3 4 15
2 0 0 0
3 1-2 0 23
Level 2 – M 160
4 1 0 4
5 1-3 5 14
6 0 0 0
Level 3 – M 180
7 1-3 3 12
8 1-2 0 14
9 1-3 6 15
10 1-3 17 28+
11 1-3 7 15
12 0 0 0
Level 4 – M 200
13 0 0 0
14 1-4 7 25
15 1-4 42 28+
WHO indicates World Health Organization; OM, oral mucositis;
M, melphalan.









140 PD SD PR
140 VGPR SD SD
140 VGPR SD BMT
160 CR CR CR
160 PR SD CR
160 CR CR REL
180 PD CR CR
180 CR CR CR
180 PR BMT BMT
200 CR REL CR
200 PD EXP EXP
200 PR PD VGPR
180 PD PR PD
180 PD PR X
180 VGPR VGPR X
PD indicates progressive disease; SD, stable disease; PR, partial re-
sponse; VGPR, very good partial response; BMT, bone marrow trans-
plant; CR, complete response; REL, Relapse; EXP, deceased.
Response and progression in this study were evaluated using the South-
west Oncology Group (SWOG) criteria for Multiple Myeloma staging.
1458 Biol Blood Marrow Transplant 18:1455-1461, 2012M. H. Abidi et al.Median baseline creatinine was 1.4 mg/dL (0.7-
2.3). All patients had Karnofsky score$70%. Thirteen
patients (87%) had stage 3 chronic kidney disease
(CKD), 1 patient had stage 4 CKD, and 1 patient had
stage 2 CKD. No patient had stage 5 CKD.
Four patients at the time of ASCT were in com-
plete response (CR), 3 patients had very good partial
response (VGPR), 5 had progressive disease (PD),
and 3 had partial response (PR). Light chain disease
was seen in 4 patients. IgG isotype was present in 8 pa-
tients. Two patients had received prior ASCTs. Ten
patients received 2 prior regimens for treatment before
the ASCT (Table 2).
Median number ofCD34 cells collectedwas 5.74
106 cells/kg (range, 4.7-13.15). Median number of
CD34 cells infused was 4.15  106 cells/kg (range,
2.58-8.03). Median number of days for neutrophil en-
graftment was 12 (range, 11-21 days). Median number
of days to platelet engraftments was 19 (range, 0-86
days). Median number of days in the hospital was 16
(range, 12-74 days). Median duration of follow-up for
surviving patients was 16.5 months (range, 3-44
months).
Melphalan was given in doses up to and including
200 mg/m2 (n 5 3) at level 4. Three patients were en-
rolled in dose level 1 (melphalan 140 mg/m2). No
DLTs were observed in level 1, so 3 patients were
added to level 2 (melphalan 160 mg/m2). Subse-
quently, 3 patients were added to level 3 (melphalan
180 mg/m2) when no DLTs were seen in level 2. Sim-
ilarly, 3 patients were added to level 4 (melphalan 200
mg/m2), and 1 death occurred in level 4 due to multi-
organ failure as the result of multiple grade 4 toxicities
and grade 3 infections.
Another patient in level 4 developed grade 3 DLTs
(congestive heart failure, interstitial pneumonitis, andbullous dermatitis). Dose escalation was stopped as 2
DLT events occurred in level 4. The next cohort of pa-
tients was added in level 3 (180 mg/m2). No DLTs
were seen in this group, hence reaching MTD.
The overall incidence of OM $grade 3 was 53%
(8 of 15), with median time to resolution of severe
OM was 6.5 days (range, 3-42 days). Patients who
did not develop any severe OM were not included in
the calculation of median and range. In level 3, 1 pa-
tient had no OM, 4 of 6 patients developed grade 3
OM and no grade 4 OM was observed. One patient
in level 3 had unresolved grade 2 OM on day 28, which
improved to grade 1 on day 35. Resolution of OM was
not documented until day 96 because the patient did
not return for follow-up visits as scheduled. Grade 4
OM was seen in 2 patients at level 4. One patient in
level 4 had delay in OM resolution. Overall, 4 of 15 pa-
tients never developed OM (Table 3). The response to
treatment at 1 year is shown in Table 4. Median dura-
tion of follow-up for patients was 16.5 months (range,
3-44 months). Of the 14 patients, 5 patients showed
CR at 1 year. Two of those patients received melpha-
lan 160 mg/m2 (level 2), 2 patients received 180mg/m2
(level 3), and 1 patient received 200 mg/m2 (level 4).
Six patients have received maintenance therapy after
the transplantation (Table 4).Non-Evaluable Group
Four patients were considered nonevaluable be-
cause they did not receive all 6 doses of palifermin.
The first patient enrolled in level 1 developed asymp-
tomatic grade 3 amylase elevation after the first 3 doses
of palifermin and was taken off the study as the palifer-
min was stopped. This patient later developed grade 3
OM during the hospital stay. Protocol was later
Table 5. Adverse Effects
Adverse Effects
Grade 1 Grade 2 Grade 3 Grade 4
Skin rash 3 10 0 0
Elevated amylase 3 3 3 0
Elevated lipase 0 1 11 0
Vomiting 5 2 0 0
Nausea 11 3 0 0
Diarrhea 8 3 1 0
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tients with asymptomatic amylase/lipase elevation.
The second nonevaluable patient enrolled in level 1
received 5 of the planned 6 doses of palifermin. The
day11 dose was accidently missed. This patient devel-
oped grade 1 OM. The third patient enrolled in level 3
received 5 doses of palifermin and developed grade 2
rash, grade 2 genital edema, and fluid retention. The
patient refused the sixth dose of palifermin and had
grade 1 OM during the hospital stay. The fourth non-
evaluable patient in level 4 developed grade 3 infection
after the first 3 doses of palifermin and, therefore,
ASCT was delayed. The patient subsequently received
melphalan 200 mg/m2 in divided doses and did not de-
velop any OM. Median duration of hospital stay for
nonevaluable patients was 14.5 days (12-23). Grade 3
skin rashwas observed in 1 patient.Grade 4 asymptom-
atic amylase elevation was seen in 1 patient and grade 3
tachycardia was seen in 1 patient. This patient also had
grade 3 dyspnea and grade 4 congestive heart failure.
No other severe toxicity was noted in this group.
Safety
All patients were monitored for adverse effects re-
lated to melphalan and palifermin up to day 100 after
ASCT. Thirteen patients developed a skin rash. Grade
1 skin rash was seen in 3 patients and grade 2 was seen
in 10 patients. Nine patients showed elevation of amy-
lase. Grade 1 was seen in 3 patients, grade 2 in 3 pa-
tients, and grade 3 was seen in 3 patients. Elevated
lipase was seen in 2 patients. One patient had grade 1
and the other had grade 2 lipase elevation. Diarrhea
was seen in 12 patients. One patient had grade 3 diar-
rhea and was also positive had a Clostridium difficile in-
fection. Eight patients had grade 1 diarrhea, and 3
patients had grade 2 diarrhea. Of the patients with
grade 2 diarrhea, 1 was also positive for Clostridium dif-
ficile. Nine patients (60%) required narcotics; 4 pa-
tients needed total parenteral nutrition/nasogastric
feeding. Seven patients had vomiting during the stay.
Grade 1 vomiting was seen in 5 patients and grade 2
in 2 patients. One of 3 patients in level 2 developed
atrial fibrillation on day 19. The patient had a known
history of atrial fibrillation. Five of 15 patients were
found to have positive blood cultures during the hospi-
talization (Table 5).One patient in level 4 developed delayed OM re-
covery. This patient had grade 3 OM until day 153.
A biopsy was performed of the lesion on her tongue,
which was consistent with pyogenic granuloma. She
received evoxac for treatment of the lesion. One pa-
tient in level 4 developed secondary graft failure, had
multiple infections, and died at day 174. This patient
was .65 years old and had received a prior ASCT for
MM.DISCUSSION
Patients with CKD are mostly excluded from clin-
ical trials using high-dose chemotherapy due to in-
creased morbidity and mortality and are thus denied
the beneficial effects of ASCT. Melphalan has a log-
linear effect on MM and a high-dose melphalan can
possibly increase the antimyeloma activity. High-
dose melphalan is associated with severe OM, which
is more significant in patients with CKD
[2,3,5,13,24]. The Food and Drug Administration
recommends decreasing the intravenous melphalan
dose by 50% in patients with BUN $30 mg/dL.
Sirohi et al. [3] evaluated glomerular filtration rate as
a surrogate marker of the outcome in patients treated
with melphalan 200mg/m2 and noted a 71% incidence
of severeOM.Badros et al. [13] in 2001 reported a 67%
grade 2 or higherOM in patients with serum creatinine
.2 mg/dL treated with melphalan 140 mg/m2. There-
fore, they recommended using amelphalan dose of 140
mg/m2. Our study has demonstrated that the melpha-
lan dose can be safely and effectively increased up to
180 mg/m2 in patients with creatinine clearance #60
mg/mL. We were successful in controlling OM with
palifermin, which is a major DLT observed in patients
with RI [2,3,5,13,24].
The incidence of severe OM observed in our study
was better as compared to other studies reported in pa-
tients with RI. TheKobbe et al. [23] study used palifer-
min 60 mcg/kg for 3 days before ASCT and observed
an incidence of severe OM to be 64% in patients with
creatinine clearance\50 mL/minute, despite the mel-
phalan dose of 140 mg/m2. This difference could be
explained by more frequent doses of palifermin
administered to our patients. We used palifermin 60
mcg/kg/day for a total of 6 days. Mucosal barrier in-
juries in the form of OM can play a significant role in
development of infections in neutropenic patients
[25-28]. Patients with RI have a higher incidence of
such complications. Sirohi et al. [3] noted an incidence
of 47%of$ grade 3 infections in patients with low glo-
merular filtration rate whowere treatedwith high-dose
melphalan. Using palifermin could lead to lower rates
of infection and sepsis in such patients by preventing
the mucosal barrier. In our study, documented bacter-
emia was observed in 5 of 15patients (33%). Three of
these 5 patients had severe OM. One patient in level
1460 Biol Blood Marrow Transplant 18:1455-1461, 2012M. H. Abidi et al.4 had grade 4 OM and grade 3 infections, which finally
resulted in death. The patient’s creatinine clearance
was 31 mL/minute. This patient was .65 years old
and had received a prior ASCT. Melphalan 200 mg/
m2 resulted in higher toxicity, including severe OM
and treatment-related mortality, which led us to de-
crease the dose back to 180 mg/m2 in the next cohort.
Most of our patients encountered the common side
effects of palifermin, including white coating of the
tongue, rash, edema, elevated amylase, and lipase,
which are manifestations of its physiological action
[29]. No grade 4 toxicity related to palifermin was
noted.Oneof our patients developeddelayedmucositis
recovery, and she continued to have a lichenoid growth
on the tongue that was not present before the treat-
ment. This area on the lateral border of the tongue
was biopsied and showed prominent granulation tissue
with acute inflammatory infiltrate compatible with
pyogenic granuloma. This may be from palifermin
use, but a definite conclusion cannot be made.
Response to treatment was a secondary objective
in our study and follow-up was restricted to 100
days posttransplantation, but the patients were still
followed off protocol and we have reported the re-
sponse at 1 year. Two of four patients who received
180 mg/m2 showed complete response at 1 year. Be-
cause some of the patients were also started on main-
tenance therapy after 100 days, it is hard to attribute
their responses to the benefits of the treatment beyond
100 days. As far as the benefit of dose escalation is con-
cerned, there is a clear advantage demonstrated in sin-
gle and tandem ASCT trials in patients with myeloma
with normal renal function. The rationale for dose re-
duction in patients with myeloma with RI is predom-
inantly opted to reduce toxicity. In the absence of
randomized trials, it is difficult to confirm or negate
the therapeutic advantages for this strategy to improve
response rate and survival. Results from single-center
studies have conflicting results for melphalan dose
ranging between 140 and 200 mg/m2. Our study is
probably the first attempt to study this group in a pro-
spective format. This issue should be evaluated in a co-
operative group setting in a randomized study.
After reviewing the medical charts of the 4 pa-
tients who were nonevaluable because they did not re-
ceive all 6 doses of palifermin, we found that severe
OM was seen in 1 patient and the other 3 developed
grade 1 or no mucositis at all. This finding could be
explained by the fact that the patient who developed
severe mucositis had a low creatinine clearance 20
mL/minute, whereas the other 3 had a creatinine
clearance .50 mL/minute.
Palifermin permitted dose escalation of melphalan
up to 180 mg/m2 with acceptable toxicity in patients
with CKD. This has the potential for further improv-
ing the outcomes of patients with myeloma who have
abnormal renal function with single ASCT. Aug-mented cell kill may be achieved in such patients
with doses of melphalan above what has been given
historically without palifermin, thus overcoming the
present-day barriers of DLTs in ASCT. The useful-
ness of palifermin could be further enhanced by using
it in conjunction with other modalities such as oral
cryotherapy, which by itself has been shown to reduce
the severity of OM in patients undergoing ASCT [30].
In this small, prospective, randomized study, 3 of 21
patients (14%) in the cryotherapy group developed
grade 3 to 4 OM compared to the 14 of 19 patients
in the normal saline group. Melphalan 200 mg/m2
dose was used as conditioning. Status of the renal func-
tion at the time of ASCT is not summarized, which
makes the comparison with patients with RI difficult.
The primary objective of our dose-finding trial was
to determine the MTD of melphalan in patients with
RI who underwent ASCT for myeloma when treated
with palifermin to prevent OM. A larger magnitude
phase 2 trial is necessary to better evaluate the anti-
myeloma efficacy of this regimen.ACKNOWLEDGMENT
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